Treatment of chronic hepatitis B: Current challenges and future directions

Reviews in Medical Virology

Volumn 13, Issue 4, 2003, Pages 255-272

  Chin, Ruth ^b   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; DNA POLYMERASE; ENTECAVIR; EPITOPE; EXONUCLEASE; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HYDROXYL GROUP; ISOLEUCINE; LAMIVUDINE; METHIONINE; NUCLEOSIDE DERIVATIVE; PHOSPHATE; PYROPHOSPHATE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; VALINE; VIRUS DNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; MUTANT; NONHUMAN; PREVALENCE; REVIEW; SEROCONVERSION; SURVIVAL; T LYMPHOCYTE; VACCINATION; VIRION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; GENES, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MUTATION; VIRUS REPLICATION;

EID: 0037765447     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.393     Document Type: Review

References (138)

1. Blumberg BS, Gerstley BJ, Hungerford DA, et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-931.
2. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1: 695-698.
3. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415.
4. Kane M. Global status of hepatitis B immunization. Lancet 1996; 348: 696.
5. Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13: 29-60.
6. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000; 32: 89-97.
7. Wong D, Cheung A, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 1993; 119: 312-323.
8. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
9. Hadziyannis S. Hepatitis Be antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7-36.
10. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-634.
11. Doong S, Tsai C, Schinazi R, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499.
12. Lai C, Ching C, Tung A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241-244.
13. Dienstag J, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087.
14. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180.
15. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532.
16. Perrillo R, Schalm S, Schiff E, et al. Predictors of HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine (abstract). Hepatology 1999; 30: 317A.
17. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus. Intervirology 1997; 40: 295-303.
18. Calio R, Villani N, Balestra E, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994; 23: 77-89.
19. Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-1673.
20. Heathcote EJ, Jeffers L, Wright T, et al. Loss of serum HBV DNA and HBeAg seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled Phase II studies. Hepatology 1998; 28: A620.
21. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134.
22. Aye TT, Bartholomeusz A, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-1153.
23. de Man R, Marcellin P, Habal F, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis Be antigen-positive hepatitis B. Hepatology 2000; 32: 413-417.
24. de Man R, Walters L, Nevens F, et al. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis. Hepatology 2000; 32: 376A.
25. Nassal M, Schaller H. Hepatitis B virus replication - an update. J Viral Hepat 1996; 3: 217-226.
26. Tavis J. The replication strategy of the hepadana-viruses. Viral Hepat Rev 1996; 2: 205-218.
27. Urban S, Fischer KP, Tyrrell DL. Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. Proc Natl Acad Sci USA 2001; 98: 4984-4989.
28. Doo E, Liang JT. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120: 1000-1008.
29. Seifer M, Standring DN. Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1. J Virol 1993; 67: 4513-4520.
30. Jacobo-Molina A, Ding J, Clark AD, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-6324.
31. Huang H, Chopra R, Verdine GL, et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance [see comments]. Science 1998; 282: 1669-1675.
32. Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 4771-4779.
33. Wu TT, Coates L, Aldrich CE, et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990; 175: 255-261.
34. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460.
35. Civitico GM, Locarnini SA. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary duck hepatocyte cultures. Virology 1994; 203: 81-89.
36. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322.
37. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minochromosomes. J Virol 1995; 69: 3350-3357.
38. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402.
39. Blum H, Stowring L, Figus A, et al. Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization. Proc Natl Acad Sci USA 1983; 80: 6685-6688.
40. Lin E, Luscombe C, Wang Y, et al. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40: 413-418.
41. Luscombe C, Pedersen J, Uren E, et al. Longterm ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatitic viral DNA, RNA and protein expression. Hepatology 1996; 24: 766-773.
42. Nicoll AJ, Angus PW, Chou ST, et al. Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection. Hepatology 1997; 25: 463-469.
43. Lee JY, Culvenor JG, Angus P, et al. Duck hepatitis B virus replication in primary bile duct epithelial cells. J Virol 2001; 75: 7651-7661.
44. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713.
45. Tipples A, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717.
46. Bartholomew M, Jansen R, Jeffers L, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22.
47. Ogata N, Fujii K, Takigawa S, et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 1999; 59: 270-276.
48. Seta T, Yokosuka O, Imazeki F, et al. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000; 60: 8-16.
49. Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-1326.
50. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
51. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-757.
52. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12: 67-71.
53. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716.
54. Melegari M, Scaglioni P, Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633.
55. Lai C, Chien R, Leung N, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
56. Thibault V, Aubron-Olivier C, Agut H, et al. Primary infection with a lamivudine-resistant hepatitis B virus. Aids 2002; 16: 131-133.
57. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-3734.
58. Locarnini S. Hepatitis B virus surface and polymerase gene variants: potential virological and clinical significance. Hepatology 1998; 27: 294-297.
59. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-1153.
60. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293: 305-313.
61. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis [see comments]. Hepatology 1998; 27: 213-222.
62. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263.
63. Bock C, Tillmann H, Torresi J, et al. HBV polymerase mutants with enhanced replication selected during lamivudine therapy result in sudden onset of liver failure. Gastroenterology 2002; 122: 264-273.
64. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of Lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'Fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping s gene. Virology 2002; 299: 88-99.
65. Xiong X, Yang H, Westland C, et al. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31: 219-224.
66. Sarafianos SG, Das K, Clark AD, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999; 96: 10027-10032.
67. Gao H-Q, Boyer P, Sarafianos S, et al. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000; 300: 403-418.
68. Dienstag J, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. NEJM 1999; 341: 1256-1263.
69. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-1088.
70. Holland J, Spindler K, Horodyski F, et al. Rapid evolution of RNA genomes. Science 1982; 215: 1577-1585.
71. Okamoto H, Imai M, Kametani M, et al. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987; 57: 231-236.
72. Coffin JM. Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol 1992; 176: 143-164.
73. Mizokami M, Orito E, Ohba K, et al. Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol 1997; 44: S83-S90.
74. Tsiang M, Rooney JF, Toole JJ, et al. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863-1869.
75. Lewin S, Ribeiro RM, Walter T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34: 1012-1120.
76. Bartholomeusz A, Schinazi R, Locarnini S. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepat Rev 1998; 4: 167-187.
77. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV infected patients. J Hepatol 1999; 30: 536-550.
78. Tillmann HL, Trautwein C, Bock T, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30: 244-256.
79. Ayres A, Bartholomeusz A, Lau GK, et al. Lamivudine and Famcicovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol 2003; 27: 111-116.
80. Herrmann EC, Jr., Herrmann JA. A working hypothesis-virus resistance development as an indicator of specific antiviral activity. Ann N Y Acad Sci 1977; 284: 632-637.
81. Richman D. Antiviral Drug Resistance: Issues and Challenges. John Wiley & Sons: Chichester, 1996; 1-9.
82. Darwin C. The Origin of the Species by Means of Natural Selection, or the Presentation of Favoured Races in the Struggle for Life, Stauffer RC (ed.). Cambridge University Press: London, 1975.
83. Niesters HG, De Man RA, Pas SD, et al. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51: 695-699.
84. Zhang YY, Summers J. Enrichment of a precoreminus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999; 73: 3616-3622.
85. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74: 5257-5265.
86. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
87. Lok AS. Treatment of chronic hepatitis B. J Viral Hepat 1994; 1: 105-124.
88. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591.
89. Yuan TT, Faruqi A, Shih JW, et al. The mechanism of natural occurrence of two closely linked HBV precore predominant mutations. Virology 1995; 211: 144-156.
90. Schalm SW, Thomas HC, Hadziyannis SJ. Chronic hepatitis B. Prog Liver Dis 1990; 9: 443-462.
91. Rizzetto M, Volpes R, Smedile A. Response of precore mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398-402.
92. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e-antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
93. Carman WF, Fagan EA, Hadziyannis S, et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14: 219-222.
94. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e-antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-624.
95. Hadziyannis SJ, Vassilopoulos D. Immunopathogenesis of hepatitis B e-antigen negative chronic hepatitis B infection. Antiviral Res 2001; 52: 91-98.
96. Milich DR, Chen MK, Hughes JL, et al. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013-2021.
97. Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599-6603.
98. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e-antigen. Hepatology 1989; 10: 198-202.
99. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-1625.
100. Hadziyannis SJ. Combination of interferon alpha therapy with non-steroidal anti-inflammatory drugs in chronic hepatitis C. Gut 2000; 46: 306-307.
101. Santantonio T, Mazzola M, Iacovazzi T, et al. Longterm follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-306.
102. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896.
103. Chen R, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 27-35.
104. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210.
105. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-307.
106. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-312.
107. Hannoun C, Horal P, Lindh M. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 2000; 81: 75-83.
108. Lauder IJ, Lin HJ, Lau JY, et al. The variability of the hepatitis B virus genome: statistical analysis and biological implications. Mol Biol Evol 1993; 10: 457-470.
109. Yamamoto K, Horikita M, Tsuda F, et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68: 2671-2676.
110. Ngui SL, Teo CG. Hepatitis B virus genomic heterogeneity: variation between quasispecies may confound molecular epidemiological analyses of transmission incidents. J Viral Hepat 1997; 4: 309-315.
111. Ogura Y, Kurosaki M, Asahina Y, et al. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 1999; 180: 1444-1451.
112. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. Hepatology 2000; 31: 819-827.
113. Gunther S, Meisel H, Reip A, et al. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology 1992; 187: 271-279.
114. Naoumov NV, Thomas MG, Mason AL, et al. Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment. Gastroenterology 1995; 108: 505-514.
115. Gunther S, Paulij W, Meisel H, et al. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology 1998; 244: 146-160.
116. Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-725.
117. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
118. Lindh M, Hannoun C, Dhillon AP, et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775-782.
119. Orito E, Mizokami M, Sakugawa H, et al. A casecontrol study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218-223.
120. Zollner B, Petersen J, Schroter M, et al. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357: 934-935.
121. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650.
122. Oketani M, Oketani K, Xiaohong C, et al. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. J Med Virol 1999; 58: 332-337.
123. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834.
124. Richman DD, Lange JM. Playing with evolution requires planning. Antivir Ther 1996; 1: 208-209.
125. Condra JH, Emini EA. Preventing HIV-1 drug resistance. Sci Med 1997; 4: 2-11.
126. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
127. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
128. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975.
129. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996; 24: 991-995.
130. Ho D, Neumann A, Perelson A, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
131. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82-85.
132. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadanaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-225.
133. Colledge D, Civitico G, Locarnini S, et al. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44: 551-560.
134. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B [In Process Citation]. Liver Transpl 2000; 6: 429-433.
135. Marques AR, Lau DT, McKenzie R, et al. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis 1998; 178: 1483-1487.
136. Lau GK, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32: 394-399.
137. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568.
138. Zeuzem S, de Man RA, Honkoop P, et al. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997; 27: 431-436.